SeaStar Medical Holding Corporation (ICU)

Revance Therapeutics Statistics

Total Valuation

ICU has a market cap or net worth of $14.80 million. The enterprise value is $9.87 million.

Market Cap	14.80M
Enterprise Value	9.87M

Important Dates

The next estimated earnings date is Tuesday, August 12, 2025, after market close.

Earnings Date	Aug 12, 2025
Ex-Dividend Date	n/a

Share Statistics

ICU has 22.59 million shares outstanding. The number of shares has increased by 271.34% in one year.

Current Share Class	22.59M
Shares Outstanding	22.59M
Shares Change (YoY)	+271.34%
Shares Change (QoQ)	+75.16%
Owned by Insiders (%)	0.97%
Owned by Institutions (%)	5.82%
Float	22.37M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	8.00
Forward PS	17.24
PB Ratio	10.74
P/TBV Ratio	26.19
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	23.05
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.96, with a Debt / Equity ratio of 0.64.

Current Ratio	0.96
Quick Ratio	0.77
Debt / Equity	0.64
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-158.16

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-144.37%
Return on Invested Capital (ROIC)	-4,324.71%
Return on Capital Employed (ROCE)	-3,135.22%
Revenue Per Employee	$22,526
Profits Per Employee	-$837,105
Employee Count	19
Asset Turnover	0.06
Inventory Turnover	n/a

Taxes

In the past 12 months, ICU has paid $6,000 in taxes.

Income Tax	6,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -92.55% in the last 52 weeks. The beta is -1.07, so ICU's price volatility has been lower than the market average.

Beta (5Y)	-1.07
52-Week Price Change	-92.55%
50-Day Moving Average	0.84
200-Day Moving Average	1.73
Relative Strength Index (RSI)	45.74
Average Volume (20 Days)	5,706,601

Short Selling Information

The latest short interest is 575,798, so 2.55% of the outstanding shares have been sold short.

Short Interest	575,798
Short Previous Month	2.95M
Short % of Shares Out	2.55%
Short % of Float	2.57%
Short Ratio (days to cover)	0.03

Income Statement

In the last 12 months, ICU had revenue of $428,000 and -$15.91 million in losses. Loss per share was -$3.04.

Revenue	428,000
Gross Profit	428,000
Operating Income	-17.71M
Pretax Income	-33.67M
Net Income	-15.91M
EBITDA	n/a
EBIT	-17.71M
Loss Per Share	-$3.04

Balance Sheet

The company has $5.30 million in cash and $363,000 in debt, giving a net cash position of $4.93 million or $0.22 per share.

Cash & Cash Equivalents	5.30M
Total Debt	363,000
Net Cash	4.93M
Net Cash Per Share	$0.22
Equity (Book Value)	565,000
Book Value Per Share	0.06
Working Capital	-248,000

Cash Flow

Operating Cash Flow	-15.17M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	100.00%
Operating Margin	-4,138.79%
Pretax Margin	-3,714.72%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

ICU does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-271.34%
Shareholder Yield	-271.34%
Earnings Yield	-107.48%
FCF Yield	n/a

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on June 10, 2024. It was a reverse split with a ratio of 1:25.

Last Split Date	Jun 10, 2024
Split Type	Reverse
Split Ratio	1:25

Scores

ICU has an Altman Z-Score of -32.3 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-32.3
Piotroski F-Score	2